Forma Therapeutics Holdings, Inc.
FMTXDelisted Oct 14, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001538927
Forma Therapeutics Holdings, Inc. was delisted on Oct 14, 2022; its insiders filed their last Form 4 on Oct 14, 2022; 139 institutions reported holding it in 13F filings for Q3 2022, worth $835.0M in total; HHLR Advisors (Hillhouse) was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:28 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 |
|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K |
| Reported | Mar 1, 2022 | Mar 30, 2021 |
| Revenue | $0 | – |
| Operating expenses | $174.0M | $124.2M |
| Research and development | $125.7M | $93.4M |
| Selling, general and administrative | $48.3M | $30.8M |
| Operating income | -$174.0M | -$124.2M |
| Income tax | $154.0K | -$29.7M |
| Net income | -$173.0M | -$70.4M |
| EPS, basic | – | $-3.22 |
| EPS, diluted | – | $-3.22 |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 |
|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K |
| Reported | Mar 1, 2022 | Mar 30, 2021 |
| Cash and equivalents | $77.4M | $282.7M |
| Short-term investments | $386.8M | $350.4M |
| Accounts receivable | – | $0 |
| Total current assets | $486.4M | $654.4M |
| Property, plant and equipment | $13.9M | $1.52M |
| Total assets | $561.1M | $681.0M |
| Accounts payable | $4.14M | $4.29M |
| Total current liabilities | $35.1M | $31.7M |
| Total liabilities | $62.7M | $32.7M |
| Shareholders' equity | $498.4M | $648.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 | FY2020 |
|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K |
| Reported | Mar 1, 2022 | Mar 30, 2021 |
| Operating cash flow | -$149.8M | -$95.4M |
| Capital expenditures | $4.18M | $249.0K |
| Free cash flow | -$154.0M | -$95.7M |
| Depreciation and amortization | $1.57M | $1.28M |
| Stock-based compensation | $22.6M | $6.96M |
| Investing cash flow | -$55.4M | -$345.8M |
| Financing cash flow | -$459.0K | $552.6M |
| Net change in cash | -$205.6M | $111.4M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 1, 2022 | 47.9M | +1.0% | SEC |
| Apr 28, 2022 | 47.8M | +0.9% | SEC |
| Feb 22, 2022 | 47.5M | +0.2% | SEC |
| Nov 9, 2021 | 47.4M | +15.2% | SEC |
| Aug 10, 2021 | 47.4M | +15.3% | SEC |
| Apr 30, 2021 | 47.4M | – | SEC |
| Mar 25, 2021 | 47.4M | – | SEC |
| Nov 6, 2020 | 41.2M | – | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.